Aortic Stenosis Treatment Market

Aortic Stenosis Treatment Market Outlook (2024 to 2034)

Worldwide revenue from aortic stenosis treatment solutions is expected to reach US$ 7.57 billion in 2024, as revealed in Fact.MR’s newly published market report. The global aortic stenosis treatment market size has been forecasted to expand at a CAGR of 9.7% and climb to a value of US$ 19.09 billion by 2034-end.

The geriatric population in the world is now more than ever before. These elderly people are more prone to developing aortic stenosis, which is driving demand for effective treatment options. Availability of improved, more effective, and patient-centric treatment is contributing to market growth. Aortic stenosis is considered the third most found cardiac disease, after coronary heart disease and hypertension. Growing expenditure for developing new treatment methods against valvular heart diseases is contributing to market prospects.

Developing more effective bio-prosthetic heart valves is one of the key innovations in the market. Currently, available surgical options available for severe aortic stenosis are tissue valves or heart valves, which are developed from animal tissues. Further, mechanical valves need medications for blood thinning, which can cause risks associated with bleeding and durability issues.

Newly developed valves are specifically designed from biomaterials mimicking natural human valves closely. These help in minimizing risks associated with aortic stenosis.

• Revenue from aortic stenosis treatment solutions in hospitals is evaluated to increase at a CAGR of 9.9% and reach US$ 11.68 billion by the end of 2034.
• Demand for aortic stenosis treatment solutions in India is analyzed to increase at a CAGR of 14.5% from 2024 to 2034.
• The market in Japan is projected to expand at a 3.7% CAGR through 2034.
• North America is projected to capture 44.3% of the global aortic stenosis treatment market share by 2034.
• Sales of aortic stenosis treatment devices in South Korea are forecasted to rise at a CAGR of 10.5% from 2024 to 2034.

Report Attribute	Detail
Aortic Stenosis Treatment Market Size (2024E)	US$ 7.57 Billion
Forecasted Market Value (2034F)	US$ 19.09 Billion
Global Market Growth Rate (2024 to 2034)	9.7% CAGR
Market Share of Transcatheter Aortic Valve Replacement Segment (TAVR) (2034F)	67.9%
Western Europe Market Share (2034F)	14.9%
Canada Market Growth Rate (2024 to 2034)	13.7% CAGR
Key Companies Profiled	Braile Biomédica; Edwards Lifesciences Corporation; Thubrikar Aortic Valve; Medtronic Plc; AstraZeneca Plc; Micro Interventional Devices, Inc.; Abbott Laboratories; Meril Life Sciences Pvt. Ltd.; Boston Scientific Corporation; JenaValve Technology, Inc.; LivaNova PLC; CryoLife, Inc.

What is Driving Development of Effective Aortic Stenosis Treatment Solutions?

“Rising Population of Geriatric People and Technological Advancements in Healthcare”

Aortic stenosis is a prevalent condition among older adults. As the global population ages, the incidence of aortic stenosis rises, driving the need for effective treatments. Continuous advancements in medical technology, including transcatheter aortic valve replacement, minimally invasive procedures, and other treatment solutions, ensure the availability of effective options for managing aortic stenosis. All of these factors are driving aortic stenosis treatment market growth.

Which Key Issues are Encountered by Market Players?

“High Cost of Treatment and Lack of Approved Drug Therapies”

One of the prominent challenges against market growth is a lack of drug therapies approved by governing authorities, which is creating issues related to their authenticity. In addition, currently, valve replacement is used as a popular treatment option by more healthcare providers. Moreover, certain risks are associated with the preoperative procedures, which is also somewhat restraining the aortic stenosis treatment market size. The high costs of aortic stenosis treatment are also limiting opportunities for market players, particularly in developing countries.

Which Market Trends Should Start-ups Capitalize On?

“Investments in R&D Activities for Exploring Need for New Treatment Options”

New companies are investing significantly in the development of innovative therapies for use as an effective treatment against aortic stenosis. Moreover, they need to focus on expanding their presence across developing countries to generate immense profit.

Country-wise Insights

North America is evaluated to account for a share of 44.3% of the global market by the end of 2034, as mentioned in the study newly published by Fact.MR, a market research and competitive intelligence provider. The prominence of the region in the global market is attributed to the growing cases of aortic stenosis among more individuals. In addition, the presence of well-established healthcare infrastructure is also generating lucrative opportunities for market players in the region.

Why is the United States a Key Market for Aortic Stenosis Treatment Solutions?

“Presence of Well-established Healthcare System”

Attribute	United States
Market Value (2024E)	US$ 2.49 Billion
Growth Rate (2024 to 2034)	11% CAGR
Projected Value (2034F)	US$ 7.05 Billion

The United States is analyzed to hold 83.5% share of the market in North America by 2034. The country is securing a significant share of regional market revenue owing to the presence of a well-developed healthcare system. In addition, increased investment in medical R&D activities is also contributing to revenue streams for market players.

What is the Future Scenario of Aortic Stenosis Treatment in India?

“Rising Cases of Valve Diseases Driving Demand for Effective Treatment Solutions”

Attribute	India
Market Value (2024E)	US$ 451.7 Million
Growth Rate (2024 to 2034)	14.5% CAGR
Projected Value (2034F)	US$ 1.75 Billion

India is evaluated to occupy a share of 67.9% of the South Asia & Pacific market by 2034-end. Market growth is attributed to the rising cases of valve diseases. Moreover, unhealthy lifestyles along with constant improvements in the healthcare facilities are also positively influencing aortic stenosis treatment market trends.

What is Driving Opportunities for Aortic Stenosis Treatment Providers in Japan?

“Growing Population of Geriatric People More Prone to Aortic Stenosis”

Attribute	Japan
Market Value (2024E)	US$ 332.8 Million
Growth Rate (2024 to 2034)	3.7% CAGR
Projected Value (2034F)	US$ 477.9 Million

Japan is evaluated to hold 17.3% share of the market in East Asia by the end of 2034. The increasing geriatric population in the country is opening doors for providers of aortic stenosis treatment solutions. These geriatric people are more prone to aortic stenosis due to their comparatively weaker immune systems, which is generating demand for effective healthcare facilities. In addition, more people are willing to spend more on medical facilities to lead a healthy life.

Category-wise Insights

Increasing use of TAVR solutions for inoperable and high-risk patients is attributed to their assistance in shorter hospital stays, reduced invasiveness, and quicker recovery time.

Which Treatment Type Accounts for a Leading Market Share?

“Preference for TAVR Solutions for Their Minimally Invasive Nature”

Attribute	Transcatheter Aortic Valve Replacement (TAVR)
Segment Value (2024E)	US$ 4.94 Billion
Growth Rate (2024 to 2034)	10.1% CAGR
Projected Value (2034F)	US$ 12.96 Billion

TAVR is forecasted to capture a share of 67.9% of global market revenue by 2034-end. This is a minimally invasive treatment procedure used for treating aortic stenosis. With constant advancements in procedural techniques and medical technology, there is increased demand for TAVR as a preferred treatment option instead of conventional open-heart surgery.

More healthcare providers are giving preference to transcatheter aortic valve replacements among larger patient pools, especially low-risk patients, which is further generating opportunities for market players. Shorter hospital stays, reduced invasiveness, and quicker recovery times are some of the benefits of using the TAVR treatment option.

Which End User is Generating Relatively Higher Revenue Streams?

“High Demand for Aortic Stenosis Treatment in Hospitals Backed by More Effective Services”

Attribute	Hospitals
Market Value (2024E)	US$ 4.56 Billion
Growth Rate (2024 to 2034)	9.9% CAGR
Projected Value (2034F)	US$ 11.68 Billion

Hospitals are projected to contribute 61.2% share of the global market by the end of 2034. More patients with aortic stenosis are opting for hospitals due to the availability of more proficient healthcare providers. Surgery is the permanent treatment available against aortic stenosis, which is pushing more patients to visit hospitals to get access to effective treatment. In addition, facilities for regular checkups and medications for patients against aortic stenosis and minimizing complications are also driving market growth.

Competitive Landscape

Key players in the aortic stenosis treatment market are coming up with more advanced approved drugs and treatment solutions to ensure effective healthcare facilities.

For instance :

• Abbott is one of the prominent companies actively involved in discovering, manufacturing, and selling a diversified and broad line of healthcare services and products in the United States. In January 2023, the company announced approvals of its system, Navitor, by the FDA. This new generation TAVI (transcatheter aortic valve implantation) system is used prominently in treating people facing issues related to severe aortic stenosis who are at higher or extreme risks of open-heart surgery.
• Medtronic is one of the popular companies involved in developing diagnostic and therapeutic medical products. In September 2022, the company announced the expansion of its United States market with the release of the Evolut FX TAVR system. It adds features to the existing Evolut platform for enhancing predictable valve deployment and ease-of-use services.

Fact.MR provides detailed information about the price points of key players in the aortic stenosis treatment market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this newly published market report.

Segmentation of Aortic Stenosis Treatment Market Research

• By Treatment Type :

  • Transcatheter Aortic Valve Replacement (TAVR)
  • Surgical Aortic Valve Replacement (SAVR)
  • Balloon Valvuloplasty
  • Diuretics
  • Angiotensin Converting Enzyme Inhibitors
  • Beta Blockers
  • Cardiac Glycosides

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Cardiac Catheterization Labs

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East and Africa